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Although the primary function of the kidney is regulation of
the volume and ionic composition of body fluids, it is also an
endocrine organ with an important role in the regulation of
blood pressure. Some renal hormones have both vasoconstric-
tor and antinatriuretic effects (vasopressor systems) while oth-
ers have vasodilator and natriuretic effects (vasodepressor
systems). A characteristic of these systems is that they act not
only on distant target organs but also in the kidney itself (local
hormones or autacoids). For example, the renin-angiotensin,
prostaglandin, and kallikrein-kinin systems, whose activation
and actions appear to be interrelated, may participate in the
control of blood pressure not only by altering the tone of
extrarenal blood vessels, but also by directly regulating intra-
renal sodium and water excretion, perhaps by regulating renal
blood flow distribution.
The renal kallikrein-kinin system is the least well defined of
these systems, yet it has been implicated in the control of renal
blood flow and function, in the pathogenesis of hypertension,
Bartter syndrome, and renal diseases, and in the antihyperten-
sive mechanism of drugs such as diuretics and angiotensin I
converting enzyme inhibitors. However, the unequivocal role
of the renal kallikrein-kinin system in these normal and patho-
logical conditions still remains unknown.
Components of the renal kallikrein-kinin system and their
measurement
Kallikreins are serine proteases that release kinins from
plasma substrates called kininogens. The two main classifica-
tions of kallikrein are plasma aad glandular. There are also two
main forms of kallikrein substrate—low and high molecular
weight kininogens—which are found in plasma [1—4]. Plasma
kallikrein, also known as the Fletcher factor, releases kinins
only from high molecular weight kininogen, also known as the
Fitzgerald factor. Plasma kallikrein is found mainly in the
inactive form (prekallikrein), and, together with high molecular
weight kininogen and Hageman factor, is involved in the
intrinsic blood-clotting mechanism through the activation of
factor XI [2]. This system is also involved in the activation of
plasminogen to plasmin and in the organism's response to injury
and inflammation. It is not known whether plasma kallikrein,
through the release of bradykinin, is involved in the regulation
of blood pressure and flow. The plasma kallikrein system differs
from the glandular kallikrein system in its biochemical, immu-
Received for publication June 12, 1985
© 1986 by the International Society of Nephrology
nological, and functional characteristics. Table 1 demonstrates
differences between these two systems.
Glandular kallikreins are found in the kidney, pancreas,
intestine, salivary, and sweat glands, and in the exocrine
secretions of these organs. We and others have found that there
is also immunoreactive glandular kallikrein in plasma [1, 5, 6].
Further, there is evidence that blood kinins may be generated
by glandular kallikrein or kininogenases other than plasma
kallikrein [7, 8]. In humans [9] and the rabbit, 50% or more of
the urinary kallikrein is in the inactive form; in the rat 70% is
active [10], Renal kallikrein releases kinins in vitro from both
low and high molecular weight kininogen. However, the natural
substrate for this enzyme is probably low molecular weight
kininogen since a patient with a congenital deficiency of plasma
high molecular weight kininogen (Fitzgerald trait) has normal
amounts of kinins in the urine (unpublished data). Renal kal-
likrein releases kallidin (lys-bradykinin), which is partially
converted to bradykinin by an aminopeptidase present in
plasma and urine [9]. Rat urinary kallikrein is an exception
because it has recently been reported that it released bradykinin
[11]. Methionyl-lys-bradykinin is formed by uropepsin when the
urine is collected at acidic pH [9]. Kinins are inactivated rapidly
by peptidases called kininases that are found in blood and other
tissues. The two main kininases have been named kininase I
and II. Kininase I is an arginine carboxypeptidase and kininase
II, also known as angiotensin I converting enzyme, is a peptidyl
dipeptidase [12]. Other kininases have also been identified.
Figure 1 shows the structure of bradykinin, lys-bradykinin
(kallidin), and met-lys-bradykinin, as well as the cleavage sites
from kininogen by plasma and glandular kallikrein, uropepsin,
kinins of aminopeptidase, and kininase I and II.
The activity of the renal kallikrein-kinin system is inferred
usually from measurements of urinary kallikrein, However, the
activity of this system could be regulated not only by the
amount of kallikrein secreted in the tubular fluid but also by the
kininogen concentration, presence of kallikrein inhibitors, pH
and ionic composition of tubular fluid, presence of kininases,
and sensitivity of the target organs. In most studies, urinary
kallikrein excretion has been the only parameter measured, and
the activity of this system has been inferred from this determi-
nation. Further, the specificity of some methods used to mea-
sure kallikrein is questionable, thus presenting limitations that
should be considered when interpreting the information avail-
able about the renal kallikrein-kinin system.
Kallikrein can be measured by methods based on different
principles; however, it is determined frequently by its
esterolytic and amidolytic activity. In these procedures, the
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Table 1. Characteristics of glandular and plasma kallikrein
Glandular kallikrein Plasma kallikrein
Molecular weight 24,000—44,000 100,000—120,000
Isoelectric point 3.5—4.4 8.0—8.5
Substrate LMWK and HMWK HMWK
Inhibited by SBTI No Yes
Normally found as Active and inactive Inactive (prekallikrein)
Abbreviations: LMWK, low molecular weight kininogen; HMWK,
high molecular weight kininogen; SBTI, soybean trypsin inhibitor.
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Fig. 1. Structure of bradkyinin, kallidin, and met-lys-bradykinin. Solid
arrows indicate the sites of kininogen cleavage by kininogenases;
dashed arrows indicate the site of kinins cleavage by kininases.
enzyme is measured by its capability to cleave the ester or
amido bond of synthetic substrates. Although these assays are
relatively simple, they lack specificity. Another frequently used
method is based on the kininogenase activity of the enzyme. In
this method, kallikrein is measured by its capacity to release
kinins when it is incubated with kininogen, and generated kinins
are measured by either bioassay or radioimmunoassay [13].
Recently, it has been reported that a nonkallikrein urinary
esterase (esterase A) that is found in rat urine is also capable of
generating kinins; however, its kininogenase activity per
esterase unit is much lower than that of kallikrein [1]. A direct
radioimmunoassay (RIA) for measuring the kallikrein protein
moiety has also been developed. This RIA is highly specific for
glandular kallikrein; however, the method measures both active
and inactive kallikrein. This RIA has allowed the quantification
of circulating immunoreactive glandular kallikrein [5, 14, 15].
The activity of the renal kallikrein-kinin system can also be
assessed by measuring kinins that are formed in the renal
vascular compartment or by determining urinary kinin excre-
tion since kinins are the biologically active part of this system.
However, kinins are catabolizeci rapidly in the kidney and blood
and while the urine is in the bladder since urine contains
kininase activity [161. Thus, renal vein and urinary kinins may
not reflect the concentrations reached at the intrarenal site of
production.
Origin, subcellular, and cellular localization of the renal
kallikrein-kinin system
Origin. Urinary kailikrein is synthesized by the kidney. In
vitro incubation of kidney slices or suspension of the renal
crtical cells results in the secretion of kallikrein into the
incubation medium [17, 18]. When isolated rat kidneys are
perfused with fluids that contain neither prekallikrein nor
kallikrein, they produce and release active and inactive kal-
likrein in both the urine and the perfusion fluid. The kallikrein
found in the perfusion fluid appears to be secreted directly into
the vascular compartment because it is found in the perfusion
fluid of nonfiltering kidneys [19].
Recently, we found that plasma immunoreactive glandular
kallikrein increased three to four times after nephrectomy, and
that its concentration was lower in the renal venous than in
arterial blood. These data suggest that the kidney filters and
removes plasma immunoreactive glandular kallikrein [15]. Tm-
munoreactive kallikrein has been found in lymph collected from
rat kidneys [20]. However, this material was reported to be
enzymatically inactive.
A small but significant increase in immunoreactive kallikrein
in plasma was found in rats that had received a low sodium diet,
which is known to increase renal and urinary kallikrein [21].
However, salt depletion also increases kallikrein in the salivary
glands [22]; whether it also enhances its release is unknown.
Thus, the source of plasmatic glandular kallikrein is still not
clear.
A simultaneous increase in esterase activity in the renal
lymph and urine of dogs during infusion of saline has been
reported suggesting that active renal kallikrein is released in the
interstitial spaces of the kidney [4]. However, as mentioned
previously, esterolytic methods are highly unspecific, and find-
ings of this study should be interpreted with caution. The
possibility that the kidney releases kallikrein in vivo into the
vascular compartment, as shown in the perfused kidney [19],
cannot be excluded. Renal kallikrein in the interstitial and
vascular spaces of the kidney could release kinins from plasma
kininogen, thereby possibly playing a role in the regulation of
blood flow distribution. At the present time, it is unclear
whether glandular kallikreins released from kallikrein-contain-
ing organs reach the systemic circulation in their enzymatically
active form. The immunoactive material present in rat plasma
was found to be inactive [23]; however, enzymatically active
glandular kallikrein has been purified recently from human
plasma [6]. We have evidence indicating that kallikrein released
from the submaxillary glands into the vascular space can
generate kinins in the systemic circulation [8].
There are considerable amounts of protease inhibitors in
plasma that could rapidly inactivate serine proteases such as
tissue kallikrein. However, the interaction of plasma or tissue
protease inhibitors with glandular kallikrein is poorly under-
stood. Alpha2 macroglobulin does not inhibit the enzyme, and
alpha1 antitrypsin was reported either to need hours to inhibit it
[24] or not to inhibit it at all [25]. In summary, whether renal
kallikrein can release kinins either systematically and/or within
the renal circulation is still unclear.
Subcellar localization, There is no complete agreement as to
the subcellular localization of renal tissue kallikrein. Some
investigators have found kallikrein activity associated with the
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lysosomal fractions. Others have found that kallikrein was
localized mainly in the microsomal fractions [1, 3].
Evidence suggests that kaUikrein is present in plasma mem-
branes [26] with the active site facing the cell exterior [27].
Recently, it was reported that kallikrein was present in free
polyribosomes, endoplasmic reticulum, and Golgi complex
structures, and also in both the lumenal and basal membranes
by immunoelectron microscopy [281, although most of the
kallikrein was associated with the membranes that face the
urinary compartment.
Taken together, these data on the subcellular localization
suggest that kallikrein may be synthesized as prekallikrein in
the ribosomes attached to the membrane of the endoplasmic
reticulum from which it is transferred into cysternal spaces and
then to Golgi complex structures where the carbohydrate
moiety is added. Then, it is possible that these vesicles either
transform into lysosomal-like particles or directly fuse with
lysosomes where part of the prekallikrein may undergo selec-
tive proteolysis, which results in active kallikrein. Subse-
quently, the kallikrein-containing vesicles condense with the
plasma and basolateral membranes, possibly with the active site
of the enzyme facing the urinary compartment (plasma mem-
brane) and the interstitial and vascular space (basolateral mem-
brane). In vitro, membrane-bound kallikrein activity is in-
creased by incubation with phospholipase A2 and also by
incubation with lysolecithin, arachidonic acid, and mellitin [29].
This suggests that activation of phospholipases leads to com-
pounds involved in kallikrein activation. It is possible that there
is feedback between phospholipases and kallikrein since glan-
dular kallikrein was shown to be a potent stimulator of
prostacyclin release in endothelial cells apparently through
phospholipase activation [30].
At the present time, it is unknown whether kallikrein bound
to the membranes could release kinins in vivo from either
urinary and/or interstitial kininogen without being released into
the urinary and interstitial vascular spaces.
Cellular localization. Over 90% of kidney kallikrein is found
in the renal cortex, decreasing from the outer to the inner
cortex, with very little kallikrein in the medulla and papilla [31].
Isolated glomeruli have a small amount of kallikrein activity
compared to the kallikrein concentration in the total cortex.
Using the stop-flow technique we have shown that kallikrein is
secreted into the urine in the distal tubule [321. Using immuno-
histochemical techniques, several studies have shown that
kidney kallikrein in rats and humans is localized in the convo-
luted distal tubules. In these studies, no kallikrein could be
found in the collecting tubules or the area of the macula densa
[33]. However, we have evidence that kallikrein-containing
cells are associated with the juxtaglomerular apparatus in rats
(Barajas, personal communication). Simson et al [34] reported a
broader distribution of kallikrein in the rat nephron including
the proximal tubule, distal tubule, and collecting tubule near the
tip of the papilla. In the proximal tubule, kallikrein was ob-
served as reabsorption droplets. Reabsorption droplets were
also observed in the proximal tubule of human nephrons. Since
the kidney removes immunoreactive kallikrein from plasma, it
may be that these reabsorption droplets are immunoreactive
fragments of filtered glandular kallikrein that are incorporated
in this segment of the nephron by endocytosis.
We recently studied the localization of both active and
inactive kallikrein in the microdissected rabbit nephron [35,361.
We selected the rabbit because in the distal tubule where
kallikrein is probably localized, transition from one segment to
another is more abrupt than in other species. Active and
inactive kallikrein was localized in the granular portion of the
distal and cortical collecting tubules. This segment of the
nephron contains more than 85% of the active and inactive
kallikrein found in the total microdissected nephron. Very little
or no active or inactive kallikrein was found in other segments,
including the bright portion of the distal segment, which has the
macula densa. The granular portions of the distal convoluted
and cortical collecting tubules have similar characteristics both
morphologically and functionally. They form a single nephron
segment called the connecting tubule, which consists of the
connecting tubule cells and intercalated cells. Since the con-
necting tubule cells and kallikrein localized only in the granular
part of the distal and collecting segment, and since the interca-
lated cells are distributed from the granular distal tubule to the
medutlary collecting tubule, we proposed that kallikrein is
synthesized in the connecting tubule cells. Using an antibody
produced in our laboratory, Figueroa et al [28] have confirmed
recently that rat renal kallikrein is localized in connecting cells
of the distal nephron. The discrete localization of kallikrein
suggests a specific role of renal kallikrein in association with the
function of these distal nephron cells. A low sodium diet greatly
increased both active and inactive kallikrein without altering
the distribution profile and without changes in the ratio of active
to total kallikrein. This suggests that sodium restriction stimu-
lates synthesis and excretion of both active and inactive kal-
likrein from the connecting cells.
Localization of' kinin synthesis in the nephron. Kinins, the
peptides released by kallikrein from kininogen, have potent and
widespread pharmacological actions. These include vasodila-
tion, contraction of many smooth muscle preparations, in-
creased capillary permeability, lymph production, and produc-
tion of arachidonic acid metabolites through phospholipase
activiation. Kinins are also able to induce changes in the
transepithelial movements of electrolytes, increase cyclic
AMP, and induce formation of phosphoinostiosides in some
cellular systems [37].
The precise role of intrarenally formed kinins is still un-
known. Considerable amounts of kinins are present in urine [91.
They appear to be formed in the kidney and urine itself, since
pharmacological amounts of kinins injected into the renal artery
fail to appear [381. The proximal tubule is rich in kininases, thus
preventing filtered kinins from reaching the distal nephron [391.
Furthermore, Carone et al [40] have shown that when labelled
bradykinin was injected into the proximal tubule, it was almost
completely destroyed. However, when this peptide was in-
jected into the distal tubule, it appeared almost intact in the
urine. This evidence, plus the fact that renal kallikrein is
secreted into the urine at the level of the distal tubule, seems to
indicate that urinary kinins may be formed in the distal part of
the nephron. We have confirmed this possibility by using the
stop-flow technique [41]. We found that kinins are formed in the
distal nephron with the highest concentration located in the final
segment of the distal part of the nephron or even in the renal
papilla and pelvis. No evidence of kinin formation was found in
the fraction representing the proximal nephron. Freshly voided
urine, which has not been in the bladder for a long period,
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sometimes generates kinins for a short time, and then the
concentration of kinins starts to decrease. At other times, kinin
concentration decreases from the moment the urine is voided
(unpublished observations). The reason for these changes is
that urine contains not only kallikrein but also kininogen and
kininases [10]. Therefore, to measure kinins formed in the
kidney, it is necessary to collect the urine directly from the
ureters and stop the formation and destruction of kinins imme-
diately after collection. Vinci et al [42] reported a lack of
correlation between 24-hr urinary kallikrein and kinin excre-
tion; the urine specimens, however, were collected by sponta-
neous voiding. Thus, kinins could have been destroyed while
the urine was in the bladder. Nevertheless, we also found no
correlation between kallikrein and kinin excretion in urine
collected directly from the ureter of volume-expanded rats and
in the urine of human subjects that had not been in the bladder
for more than 30 mm [43, 44].
We found that acidification of the urine by infusion of sodium
sulfate decreased kinin excretion while it increased kallikrein
excretion [43]. It is possible that the lower pH within the distal
nephron decreases the kininogenase activity of renal kallikrein,
because the optimum pH of kallikrein is 8.5. This suggests that
changes in the basal urinary pH level influence the urinary
excretion of kinins. Recently, Kauker et al [45] reported that
the urinary excretion of kinins varied in relation to the urinary
level of vasopressin, irrespective of urinary volume, osmolar-
ity, or kininogenase activity. These data again indicate that the
intrarenal formation of kinins is determined not only by kal-
likrein but also by other factors.
When bradykinin is infused into the renal artery, 90% is
inactivated in one passage through the kidney and less than
0.25% appears in the urine [38]. Among kininases, kininase II
has been studied more extensively than kininase I, partly
because kininase II hydrolyzes kinins and also converts angio-
tensin I to angiotensin II. Kinins could be considered the
preferred substrate for kininase II, since the Km is lower for this
peptide than for angiotensin I. Kininase II has been localized in
the brush border of the proximal tubule cells of the kidney using
fluorescent-labelled antibody to kininase II and also by demon-
strating a high concentration of this enzyme in brush bordered
membranes that were separated by differential centrifugation
[46]. Small concentrations of kininase II were also found in the
distal nephron. The presence of kininase II and other peptidases
in the lumen of the proximal tubule prevents filtered kinins from
reaching the distal nephron, thus acting as an effective barrier
[40].
Renal lymph also contains kininase II. A carboxypeptidase
distinct from carboxypeptidase A, B, or N has been purified
from human urine [47]. Despite the presence of these kinin-
inactivating enzymes, large amounts of kinins are found in urine
[9]. It could be that kininases are only weakly active at the
acidic pH normally found in urine.
The origin of the kininogen (substrate) needed for the forma-
tion of kinins in the lumen of the nephron is not known. The
plasma of different species are rich in kininogen. The amount is
on the order of 4 to 12 g/m1 when expressed as its capability to
release kinins when incubated with trypsin. A small amount of
plasma kininogen reaching the distal nephron could account for
the kinins found in the urine. In human urine, there is a
significant amount of immunoreactive kininogen; however,
Fig. 2. Localization of the kallikrein-kinin system, renin, and prosta-
glandins in the nephron (right brackets), anatomical subdivisions of the
nephron (far left brackets), and type of cells found in the distal
nephron(left brackets).
kininogen is found in only small amounts when measured by its
capability to generate kinins [91. It could be that most of the
kininogen has already been consumed by the urinary kallikrein.
It has been reported that urinary kinins were absent in a subject
who had a congenital deficiency of low and high molecular
weight kininogen [9]. On the other hand, as previously men-
tioned, it was found in a patient who did not have high
molecular weight kininogen but who had near normal low
molecular weight kininogen (Fitzgerald trait), that the urine
contained normal amounts of kinins. This indicates that kinins
in the urine are formed from low molecular weight kininogen
and that they are not formed by plasma kallikrein, because this
enzyme mainly uses high molecular weight kininogen as sub-
strate [31. Plasma kininogen appears to be synthesized by the
liver [3].
Recently, Proud et al [48] isolated kininogen from human
urine by immunoaffinity chromatography. Using immunofluo-
rescence techniques with an antibody against the heavy chain of
kininogen, Proud et al [481 localized kininogen in the cortical
and medullary distal tubules and in the collecting ducts, which
suggests that urinary kininogen originates in the distal nephron.
However, in the renal tissue of rabbits, we have been unable to
demonstrate the presence of kininogen (Omata, Scicli, and
Carretero, unpublished results). The presence of an inhibitor of
glandular kallikrein has also been demonstrated in the tubules
of the rat kidney [49]. It is feasible that this inhibitor could play
a role in the regulation of the intrarenal formation of kinins.
Figure 2 illustrates the localization of kinin synthesis and
degradation in the kidney.
Interrelations between the kallikreinin-kinin system and other
hormonal systems. The renal kallikrein-kinin system can acti-
vate both the renin-angiotensin and prostaglandin systems.
Urinary kallikrein in vitro converts inactive renin to active
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renin; a suggestion was made that it could also activate renin in
vivo. However, urinary kallikrein appears to hydrolyze only
inactive renin that has been exposed previously to acidic pH
[50, 51].
There is evidence indicating that both urinary kallikrein and
kinins can stimulate release of renin. Suzuki et al [52] reported
that urinary kallikrein stimulates release of renin from
superfused isolated kidney slices. Neither bradykinin in high
doses nor trypsin (a potent kininogenase) was able to release
renin under these experimental conditions, indicating that kal-
likrein was acting by mechanisms other than the generation of
kinin. The effect of urinary kallikrein on renin release was
blocked by aprotinin, a nonspecific protease inhibitor and
amiloride, which in high concentration is also able to inhibit
kallikrein [30]. The effect was not blocked by indomethacin or
propanolol. The same laboratory has recently re-examined
these data. They suggest that the previous observation was not
due to renin stimulation but rather to the higher recovery of
renin after freezing and thawing in the samples that contained
proteins [53]. It is not clear, however, why aprotinin, a poly-
peptide, or amiloride, a low molecular weight organic com-
pound, could prevent the protective effect of proteins on renin
activity. The effects of glandular kallikrein on renin release
were further studied by our laboratory [54]. We found that
either hog or rat submandibular kallikrein can stimulate renin
release from isolated superfused rat glomeruli. This effect could
not be explained by unspecific protection of renin because it
occurred in the presence of 0.1% BSA and was abolished by
treatment of kallikrein with aprotinin or phenylmethylsulpho-
nylfluoride (a serine protease inhibitor). These data leave open
the possibility that kallikrein, or a closely related enzyme, plays
a role in the activation of renin release; however, the physio-
logical significance of the in vitro effects of kallikrein on renin
release are unclear at this time. In vivo, bradykinin infused into
the renal artery of dogs stimulates renin release [54]. In vitro
kinins increased renin release from isolated superfused
glomeruli [55]. It may be that Suzuki et al [52] did not observe
similar effects with kidney slices because kininases degraded
kinins rapidly.
Aprotinin, an unspecific serine protease inhibitor, inhibited
renin release in humans and furosemide-stimulated renin re-
lease in rats and rabbits [56—58]. It is still unclear whether these
effects of aprotinin are due to inhibition of glandular kallikrein
or other serine proteases or are unrelated to its inhibitory
activity. Additional studies using different kallikrein or protease
inhibitors are needed to clarify this point.
The angiotensin I converting enzyme (kininase II) further
links the kallikrein-kinin and renin-angiotensin systems [12].
The converting enzyme is found in high concentrations on the
endothelial cell surface of the lung's vascular bed and has the
concurrent functions of converting angiotensin I to II and
destroying kinins. There is evidence that over 90% of the kinins
administered in the venous side of the systemic circulation are
destroyed by one passage through the lung, which suggest that
most of the intrarenally formed kinins that might enter the renal
venous blood would be destroyed before they reach the periph-
eral circulation. This suggests that kinins formed intrarenally
act as vasodilators within the confines of the renal vasculature,
perhaps regulating blood flow to specific areas in the nephron.
Mineralocorticoid administration increases urinary kallikrein
excretion and renal kallikrein concentration while spirolactone,
an aldosterone antagonist, decreases it [1, 3, 4, 18]. These
findings suggest that renal kallikrein is regulated by
mineralocorticoids. However, the increase in kallikrein occurs
in vivo after the mineralocorticoids induced changes in renal
function. In dogs treated with deoxycorticosterone acetate
(DOCA) kallikrein increased after the dogs had escaped from the
sodium-retaining effects of the steroid [60]. In microdissected
nephron segments from rabbits the transepithelial voltage of the
connecting tubule where kallikrein is located is independent of
DOCA, while that of the light portion of the cortical collecting
tubule is affected by mineralocorticoids [1]. It was reported
recently that adrenalectomy decreased the content of both
active and inactive kallikrein in connecting tubules as well as
that of Na-K-ATPase in cortical and medullary collecting
tubules [61]. After aldosterone injections, Na-K-ATPase re-
turned to normal values while the content of kallikrein remained
depressed. Thus, kallikrein does not appear to be regulated
directly by mineralocorticoids. We feel that the accumulated
data suggest an indirect action of corticosteroid hormones on
the synthesis and release of renal kallikrein, perhaps through an
alteration of water and electrolyte metabolism.
Kinins infused into the renal artery stimulate the synthesis of
prostaglandins, probably prostaglandin B2 (POE2), in the col-
lecting duct and renal medulla and prostacyclin (PGI2) in the
arterioles [1, 3, 4].
This effect of kinins is the result of acylhydrolase stimulation,
which leads to arachidonic acid release from phospholipids, and
thereby provides substrate for the formation of cyclooxygenase
and lypooxygenase products. Several studies suggested that
some of the effects of kinins in renal function relate to concom-
itant prostaglandin generation. It was reported that part of the
renal vasodilator and natriuretic effects of kinins can be inhib-
ited by cyclooxygenase inhibitors. However, these findings
have not been confirmed in subsequent studies [62]. Kinins
generated intrarenally appeared to stimulate release of a POE-
like substance from an isolated rabbit kidney that was perfused
with Krebs' solution containing kininogen. Kinins induced the
release of various prostanoids including POE2 and 6-keto-
POFia from rabbit renal papillary collecting cells in culture [63].
Kinins are also able to stimulate prostaglandin synthesis from
rat kidney mesangial cells [64]. Monolayers of canine cortical
collecting tubule cells responded to bradykinin stimulation with
prostaglandin release only when the kinins were added to the
apical surface, which suggeted that urinary but not blood-borne
kinins elicit prostaglandin formation in these cells [65]. Inter-
estingly, prostaglandins were released from both the apical and
basolateral surface. Prostaglandins have been reported to stim-
ulate urinary kallikrein excretion [4], while phospholipase A2
can activate membrane-bound renal kallikrein [26].
Mineralocorticoids can increase urinary kallikrein and POE2
simultaneously. The increased excretion of POE7 in DOCA-
treated rats was found to be decreased by administration of
aprotinin, an unspecific serine protease inhibitor [66]. Prosta-
glandins stimulate, while cyclooxygenase inhibitors suppress,
kallikrein release [62]. Angiotensin, another prostaglandin re-
leasing agent, has also reported to stimulate renal kallikrein
excretion [4].
These data suggest that kinins formed in the distal nephron
may stimulate production of prostaglandins, particularly by the
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cells of the collecting duct, interstitial cells of the renal medulla,
and endothelial cells of blood vessels. Kallikrein by itself
appears to be a potent stimulator of PG!2 release from
endothelial cells in culture [30]. Kallikrein release and
prostaglandin production may be linked under circumstances
not yet well defined.
The interactions between the kallikrein-kinin system, renin
angiotensin-aldosterone, and prostaglandin systems may play
an important physiological role. It could be speculated that an
increase in renin-angiotensin system activity would produce
both a peripheral and renal vasoconstriction that could impair
renal blood flow. However, angiotensin II and aldosterone
stimulates the release of renal kallikrein and prostaglandins,
which could produce local vasodilation and maintain renal
blood flow.
Antidiuretic hormones may also be linked to the renal kal-
likrein-kinin system. Antidiuretic hormone (ADH) stimulates
both the release of kallikrein and intrarenal formation of kinins
[67]. Bradykinin acts only from the basolateral surface of rabbit
collecting tubules to antagonize the hydrosmotic effects of
ADH; this effect appears to be mediated through prostaglandins
[68]. It is possible that intrarenally formed kinins antagonize or
modulate the effects of ADH in the kidney either directly or
through the release of prostaglandins.
In conclusion, there are numerous complex interactions
among the kallikrein-kinin, renin-angiotensin-aldosterone,
ADH, and prostaglandin systems of the kdiney. Many are not
completely understood. Some may be of no physiological
importance. In these systems abnormalities have been observed
that suggest that the interaction of kinins, renin, and prosta-
glandins may play an important role in the regulation of renal
function in physiological and pathological situations.
Physiological role of the renal kallikrein-kinin system
Although some of the actions of renal kallikrein may be due
to its catalytic effect on substrates other than kininogen, most of
its effects seem to be mediated by kinin release.
The evidence indicating a role for the renal kallikrein-kinin
system in the regulation of renal vascular resistance is mostly
indirect. Infusion of kinins into the renal artery increases renal
blood flow, diuresis, and natriuresis. The increase in blood flow
is greater in the outer than in the inner cortex [1]. These effects
on renal function are common to most vasodilators and by
themselves only suggest that the kidney has receptors for
kinins. It is unlikely that arterial injections of kinins mimic the
effects of kinins endogenously generated by renal kallikrein,
since the sites of action, the concentration, or the sequence of
vascular elements affected may be different. It has been re-
ported that administration of inhibitors of kininase II (such as
captopril), induces increase in the renal blood flow and of renal
venous blood and urinary kinins [1]. Thus, it is possible that
part of these effects are due to an increase in the intrarenal
concentration of kinins. However, these types of studies do not
discriminate between the effects that result from kinins from
those that result from the inhibition of conversion of angioten-
sin Ito the powerful vasoconstrictor angiotensin II. In sodium-
depleted dogs, it is likely, for example, that the changes induced
by kininase II inhibitors are due to lowering of angiotensin II
since the infusion of an angiotensin antagonist produced the
same changes [3]. However, Clappison et al [69] found that
dogs in which the renin-angiotensin system was inhibited by
pretreatment with DOCA and a high salt diet, or by simulta-
neous infusion of an angiotensin antagonist, still responded to
kininase inhibitors with the same qualitative changes in renal
blood flow. Another recent study showed that sodium-depleted
rats did not have an increase in renal blood flow when they
received infusion of kinins. The response to kinins was, how-
ever, restored if the rats were administered pretreatment with
aprotinin. In addition, rats on a high sodium diet responded
normally to kinins infusion. In these sodium-repleted rats, the
renal vascular resistance was decreased by a kininase II inhib-
itor, but it was not affected by saralasin, an angiotensin antag-
onist. Interestingly, the action on renal blood flow of captopril
was blocked by aprotinin [70]. These data were interpreted as
suggesting that the influence of the kallikrein-kinin system upon
renal vascular resistance was maximal during sodium depletion
and, also, that the increase in renal blood flow induced by
captopril when on a high sodium was due to a decrease in the
inactivation of kinins. Again these studies do not differentiate
between kinins generated locally by renal kallikrein or system-
ically by plasma kallikrein. However, aprotinin is a poor
inhibitor of plasma kallikrein [2]. To influence renal vascular
resistance, kallikrein should be released into the basolateral
membrane side and generate kinins, which then should gain
access to the vascular smooth muscle of the glomerular arteri-
oles. The evidence for this is conflicting. As described before,
Rabito et al [15] found that there is less immunoreactive
glandular kallikrein in arterial plasma than in renal vein plasma.
No evidence of increased kallikrein in renal lymph was found
by Proud et al [20]. These data do not favor the notion of a
passage of renal kallikrein into the interstitial space. However,
this possibility cannot be discarded. Isolated perfused kidneys
release kallikrein into the perfusate, thus indicating release into the
interstitial space [13, 19]. Whether this finding can be extrapolated to
an in vivo situation is not as yet clear. Anatomically, release into the
basolateral side is possible since kaffikrein has been found in baso-
lateral membranes [29]. Using electronimmunocytochemistry,
Figueroa et al [28] recently showed that a small percentage of the
kallikrein present in connecting cells of the distal nephron appears to
be incorporated to and released from the basolateral membrane.
Studies with specific inhibitors of glandular kallikrein may have to be
performed before the role of the renal kallikrein-kinins system in
regulation of renal vascular resistance can be clearly understood.
Unlike other vasodilators, kinins do not induce diuresis and
natriuresis by decreasing proximal sodium and water reabsorp-
tion in outer nephrons, as determined by micropuncture [1, 3],
In consequence, kinin-induced natriuresis is either due to
inhibition of sodium reabsorption in the distal part of the
nephron or in deep proximal nephrons not available for micro-
puncture. Kinins may affect sodium reabsorption as a result of
a direct effect on sodium reabsorption in the nephron or
because of changes in the osmotic gradient in the renal medulla
or both. Changes in the osmotic gradient of the renal medulla
could explain the decrease in urinary osmolarity and vasopres-
sin-resistant diuresis caused by kinins [1, 31. The medullary
osmotic gradient may have been changed by the increased
blood flow brought about by the peptide and/or by decreased
reabsorption from the distal nephron. To our knowledge, stud-
ies on changes in medullary blood flow during kinin adminis-
tration have not been reported.
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As noted before, kinins administered intrarenally probably do
not mimic the effects produced by kinins formed intrarenally
since their site of action or concentration could be different.
However, a study conducted by Kauker [71] suggests that
lumenal kinins could indeed be natriuretic. He has shown that
kinins administered in the late proximal nephron could double
the excretion of 22Na, which was simultaneously perfused into
the tubule [71]. This study should be interpreted with caution,
however. The enhancement by kinins of sodium excretion
could have occurred proximal to the distal and collecting
tubules where kinins are formed. Normally, kininases present
in the proximal nephron would presumably metabolize any
filtered kinins. Thus, the effects of kinins are expected to occur
either at the site of production or downstream from it. In
addition, Kauker [71] used only one concentration of kinins
(100 pg/nl), which is much higher than the concentration that
can be found in the nephron, since a rat kidney excretes less
than 1000 pg of kinins/ml urine during water diuresis [43].
Nevertheless, these data indicate that decreased sodium reab-
sorption occurs when kinins are present within the lumen, at
least under the conditions used by Kauker [71]. This is also
suggested by other circumstantial evidence; the administration
of aprotinin, an inhibitor of proteases, to volume-expanded rats
decreased glomerular filtration rate, renal blood flow, urinary
sodium, potassium and PGE2. Furthermore, the administration
of antibodies against kinins to saline-expanded rats has been
reported to result in a decrease in sodium excretion [1, 3, 4, 72].
These findings indicate that endogenously released kinins cause
natriuresis, diuresis, and also intrarenal release of prostanoids.
Again, however, these types of studies do not clearly distin-
guish between kinins generated by either plasma or renal
kallibein. Kinins applied to the lumenal side of isolated rat
colon produced no changes in either sodium fluxes or short-cir-
cuit current. In contrast, large increases in short-circuit current
were observed when kinins were applied to the antilumenal
side, due principally to augmented chloride movement toward
the lumen of the colon [73]. These effects were attenuated by
the administration of furosemide and a cyclooxygenase inhibi-
tor. These studies were performed with a concentration of
kinins (1 itM), which was 500.000-fold lower than that used by
Kauker [711 and is presumably a physiological concentration.
These data do not suggest that lumenal kinins affect either Na or
Cl movement, at least in the colon. It is of interest that the
antagonist action of kinins over vasopressin in isolated rabbit
tubules was also exclusively seen when applied to the
antilumenal side and appeared to be prostaglandin-dependent
[68]. However, aprotinin and 1D-phe-D-phe-L-arg-chlorometh-
yl ketone, which are kallikrein inhibitors, reduce to a greater
extent short-circuit current in the bladder of toads when they
are on the mucosal side [3], presumably by inhibiting a kal-
likrein-like enzyme. All these data, including those obtained in
the rat colon, suggest that kinins generated intrarenally either
on the basolateral side and/or the lumen of the distal nephron
are saluretic.
If one assumes that changes in the intrarenal formation of
kinins are reflected by changes in the excretion of kallikrein,
then the known data are much more controversial. However,
this assumption has never been substantiated. In fact, our
studies and those of others show that measuring the urinary
excretion of kallkrein does not reflect the intrarenal formation
of kinins [1, 9, 43, 44]. This should be expected since the
concentration of the enzyme in urine is much higher than that of
substrate [10]. Further, variations in urinary pH, ionic concen-
tration of the urine, kininases, and the possible presence of
inhibitors indicate that kinins released by kallikrein within the
kidney may not be reflected by kallikrein measurements.
Urinary kallikrein excretion has been found to correlate
inversely with dietary salt intake while high potassium intake
has been shown to increase urinary kallikrein excretion [3].
These effects may be secondary to an increase in aldosterone
secretion. High kallikrein excretion has been noted in most but
not all patients who have primary aldosteronism and in those
who have Bartter syndrome; these are conditions characterized
by high aldosterone secretion [1, 74]. However, high aldoster-
one secretion is not always accompanied by high kallikrein
excretion. Rats that have 2-kidney, 1-clip renovascular hyper-
tension have normal or high plasma aldosterone concentrations,
low kallikrein excretion, and low renal tissue kallikrein concen-
trations. Furthermore, an excess of mineralocorticoids does not
always produce high kallikrein excretion [1, 3, 4, 75]. There-
fore, other still unidentified factors control renal kallikrein
excretion.
In humans, dexamethasone and ACTH also significantly
augment the excretion of kallikrein [76, 77]. Hypertensive doses
of dexamethasone resulted in suppression of urinary kallikrein
[78].
Water loading has been found to increase kallikrein excre-
tion; however, this finding is not universal [1, 3, 4]. Diuretics
increase urinary kallikrein excretion, an effect that appears to
be independent of their site of action in the nephron [3].
Acetazolamide, which acts in the proximal tubule, furosemide
and bumetanide, which act on Henle's loop, and thiazides,
which act on the distal tubule, increase kallikrein excretion.
The increase in urinary kallikrein excretion significantly corre-
lates with the excretion of sodium, potassium, and water.
Because diuretics stimulate the secretion of aldosterone, it may
be assumed that their effect on kallikrein excretion is mediated
by this mineralocorticoid. However, diuretics stimulate kal-
likrein excretion within a few minutes of administration, while
aldosterone increases kallikrein excretion only after 3 or more
days of administration. Thus, aldosterone does not mediate the
acute effects of diuretics. It could be that part of the natriuretic,
diuretic, and antihypertensive effects of diuretics is due to
increased kinin formation. However, it has been reported
recently that amioride, a diuretic that inhibits sodium entrance
into the distal tubule cell from the lumenal side, inhibits the
enzymatic activity of urinary kallikrein in vitro [30]. We found
that the excretion of kallikrein and of kinins were depressed
after acute administration of amioride [43]. Thus, the role of
the kallikrein-kinin system in the mechanisms of action of
diuretics needs further definition. The modification of kallikrein
release induced by diuretics suggest a link between the cellular
changes induced by diuretics and the mechanisms controlling
kallikrein release. However, these diuretic-induced changes
may be an epiphenomenon associated to the augmented urinary
volume and electrolyte excretion induced by the drugs.
In conclusion, the above-mentioned data suggest that the
kalllkrein-kinin system is involved in the regulation of electro-
lyte and water transport by the distal part of the nephron. These
effects could be due either to a direct effect of kinins on sodium
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transport in the distal nephron, to changes in renal blood flow
distribution, or to both.
Renal kallikrein-kmin system in human and experimental
hypertension
The theoretical possibility that hypertension results from
either an excess of vasopressor substances or from a deficiency
of vasodepressor substances has stimulated research on the role
of the renal kallikrein-kinin system in the pathogenesis of
various types of human and experimental hypertension. Fur-
thermore, the kidney, which is considered one of the most
important determinants in the long-range control of blood
pressure, has both vasopressor (renin-angiotensin system) and
vasodepressor (kallikrein-kinin and arachidonic acid metabo-
lites) components. These vasoactive substances could also par-
ticipate in the regulatory capacity of the kidney to excrete
sodium and water.
There are many reports indicating that urinary kallikrein
excretion is decreased in patients who have essential hyperten-
sion [1, 3, 4]. However, there are indications that if variables
such as renal function and race are considered, urinary kal-
likrein excretion in hypertensive and control subjects is com-
parable [79]. Persons of the black race have lower kallikrein
levels than white persons [791, and patients who have low
creatinine clearance have depressed levels of kallikrein [80, 81].
However, we and others 1 1, 3, 82—84] have reported that
kallikrein excretion is decreased in patients who have essential
hypertension and normal renal function when compared with
normotensive control subjects who have been matched for age,
race, and sex. The reason for the discrepancy among these
studies is unknown. It is interesting to note that many hyper-
tensive patients have normal kallikrein excretion whereas oth-
ers have conspicuously low amounts of kallikrein.
Most but not all patients who have primary aldosteronism
have increased kallikrein excretion while those who have
renovascular hypertension have decreasd kallikrein excretion,
despite secondary aldosteronism [1, 3, 4]. These data indicate
once again that although mineralocorticoid activity is an impor-
tant regulator of renal kallikrein, further regulatory mechanisms
exist.
In an epidemiological study in which urinary kallikrein con-
centration (esterase activity) was measured in a large popula-
tion of healthy children and their mothers, there was a signifi-
cant familial clustering of urinary kallikrein excretion [84].
Urinary kallikrein concentration was significantly lower in
black than in white children. It was altered by season (lower in
summer) and by time of day (highest in morning). Families with
the lowest mean kallikrein concentrations tended to have higher
blood pressure than families with the highest kallikrein concen-
trations, suggesting concomitant and genetic influence on both
blood pressure and kallikrein excretion. This study involved
more than 600 children and 163 families; measurements were
made in spot urine samples. Uchiyama et al [85] recently
reported in a brief communication that no relationship between
blood pressure and urinary kallikrein was found in a study
involving 77 healthy Japanese children. These conflicting re-
sults indicate that the genetic relationship between blood pres-
sure and renal kallikrein has not yet been elucidated.
In this regard, it is interesting to note that urinary kallikrein
excretion is decreased in three different models of genetically
hypertensive rats developed by selective inbreeding on the
basis of their blood pressure [86—89]. Perhaps one of the genetic
loci, which controls blood pressure, is linked to one that
controls renal kallikrein. At the present, it is unclear whether
these are concomitant phenomena, functionally unrelated to
each other, or whether the decrease in kallikrein excretion is a
pathogenetic factor in the development of hypertension. An-
other possibility is that the kallikrein excretion is decreased
secondary to the increase in blood pressure; however, de-
creased urinary kallikrein is seen in normotensive children of
patients who have essential hypertension and also in rats of the
New Zealand genetically hypertensive strain of rats, and the
fawn-hooded spontaneous hypertensive rats [1, 3, 89] before
they develop hypertension. Urinary kallikrein excretion is
decreased in rats bred to be susceptible to the hypertensive
effects of salt (Dahl salt-sensitive rats) [14]. Thus, it is possible
that the decreased activity of the kallikrein-kmin system re-
sulted in decreased capacity to eliminate excess water and
sodium, hence leading to hypertension. However, Dahi's rats
have proteinuria when they receive a high salt diet. Rats with
proteinuria have higher concentrations of protease inhibitors in
their urine. It has been suggested that lower kallikrein in the
Dahl rats is due not to decreased synthesis but rather to
increased inhibition. When salt-resistant and salt-sensitive rats
are raised on a low sodium diet both strains have similar blood
pressure and kallikrein excretion [90]. Urinary kallikrein is not
always found decreased in genetic experimental hypertension.
Stroke-prone spontaneous hypertensive rats and genetically
hypertensive mice have increased kallikrein when compared
with their respective controls [3].
It is possible that kallikrein excretion is lower when there is
an underlying abnormality in renal function, but not when the
kidney is uninvolved in the pathogenesis of the hypertension.
Lower activity of the kallikrein-kinin system may contribute to
decreased capacity to excrete a sodium load in some patients
who have essential hypertension and low kallikrein. In addition,
decreased kallikrein in urine may not by itself cause abnormal
renal function, but it may indicate that the normal mechanisms
of synthesis and release of proteins from the distal nephron are
altered.
As in humans, rats that have renovascular hypertension have
decreased kallikrein in renal tissue and in urine [88, 75]. In two
kidney-one clip Goldblatt hypertensive rats, urinary kallikrein
was decreased only in urine from the stenotic kidney, while that
of the contralateral kidney was normal [91]. It may be that the
decrease in urinary kallikrein is related to decreases in renal
blood flow as suggested by studies in humans and dogs [3, 4,
79]. Thus, there is coincidence between the general trend
observed in human patients and the response in the experimen-
tal models. Overlack et al [92] showed that patients who have
essential hypertension and low amounts of kallikrein responded
to the oral administration of hog glandular kallikrein with a
significant fall in the blood pressure. However, this study needs
to be confirmed.
In conclusion, urinary kallikrein decreases frequently in
patients and animals with primary or secondary hypertension,
with the exception of mineralocorticoid-induced hypertension
where it is increased or, in some cases, normal. It is not yet
clear whether abnormalities in the excretion of kallikrein reflect
similar changes in the intrarenal formation of kinins. Reliable
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measurements of urinary kinins in patients and experimental
animals are scarce. In any case, it has not been proved that a
depressed kallikrein-kinin system may have a pathogenetic role
in hypertension.
Renal disease and related conditions
Urinary kallikrein excretion is significantly decreased in rats
with acute renal failure produced by methemoglobin injection
[I]. Kallikrein excretion is also low in other experimental
models of acute renal failure [1, 3, 4]. In patients who have
chronic renal failure, kallikrein excretion is normal or de-
creased 1811. However, kallikrein excretions increased greatly
when expressed per milliliter of glomerular filtration rate. In
patients who have acute tubular necrosis of the vasomotor type,
kallikrein reached its highest peak just prior to the resolution of
the oliguria [931. An increase in kallikrein activity per nephron
may help in the maintenance, or promotion of better excretory
functions and/or blood flow, in the injured kidney.
There are few reports on kalhkrein excretion in renal trans-
plant subjects. In humans and dogs, kallikrein is decreased and
it has been reported that it decreases even further during
rejection [1, 3, 4]. Brouhard et al [94] found that urinary
kallikrein increased just prior to the rejection episode. It has
also been claimed that amounts of kallikrein are lower in
hypertensive than in normotensive graft recipients [95]. These
studies should be interpreted with caution since the methodol-
ogy used to measure kallikrein (esterase activity) is not specific
for this enzyme, Recently, in a sutdy in which kallikrein was
measured by radioimmunoassay, it was confirmed that kal-
likrein excretion in graft recipients is lower than in control
subjects, but no differences were observed before and during
rejection or in relation to blood pressure. Amidolytic and
esterolytic activity was observed to increase prior to rejection
but immunoreactive ka!likrein did not change [961. Depressed
urinary kallikrein may be related to the diminished functional
tubular mass of these patients. Esterases other than kallikrein
may appear in urine prior to rejection, although more informa-
tion is needed before elucidating this point. Patients who had
cirrhosis without renal failure showed significantly higher
amounts of kallikrein than healthy subjects, perhaps because of
concomitant secondary hyperaldosteronism. In contrast, pa-
tients who have cirrhosis with renal failure had much lower
kallikrein excretion than those with maintained renal function,
although plasma renin activity and aldosterone are very high
[97]. It could be that the kallikrein-kinin system is involved in
the maintenance of renal function and blood flow in these
patients. Impaired production of kallikrein may contribute to
renal failure. Alternatively, decreased kallikrein may reflect
impaired tubular function and compromised renal blood flow.
Urinary kallikrein excretion is decreased in the early phase of
experimental nephritis that has been induced by antiglomerular
basement membrane antibodies and in nephrosis that had been
induced aminonucleosides [98]. In antiglomerular basement
membrane nephritis, the fall in kallikrein excretion occurs
within the first 24 hr concurrent with the onset of proteinuria. In
aminonucleoside nephrosis, the decrease precedes the onset of
proteinuria by 48 hr, beginning 24 hr after aminonucleoside
injection. In experimental chronic glomerulonephritis in rats,
kallikrein excretion is normal [99].
It is conceivable that the decrease in kallikrein excretion
frequently observed in different acute renal diseases partici-
pates in the pathogenesis of these diseases. However, this
contention needs further support.
Summary
In the last decade, our knowledge of the renal kallikrein-kinin
system has been advanced significantly. More specific and
sensitive methods for assessing its activity have been devel-
oped. Further, it has been found that in the kidney this system
is localized in the distal nephron, where it appears to be linked
to processes that control water and electrolyte excretion. Data
indicate that the kallikrein-kinin system interacts with other
renal hormonal systems such as the prostaglandin and renin-
angiotension-kinin system may participate in the control of
renal function and the pathophysiology of renal diseases. An
increase in kallikrein excretion has been observed after admin-
istration of antihypertensive drugs. The kallikrein-kinin system
may therefore participate in their mechanism(s) of action.
Our current knowledge suggests that the renal kallikrein-
kinin system is an integral part of the intrarenal hormonal
system that controls water and electrolyte excretion and par-
ticipates in the regulation of blood pressure.
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